Affiliation:
1. ԵՊԲՀ, Ընդհանուր ուռուցքաբանության ամբիոն
Abstract
In this literature review, we have described the current approaches of targeted therapy and immunotherapy in the treatment of relapsed ovarian cancer. Main clinical trials and accepted standard treatments in this sphere are presented. Challenges in the treatment of patients with relapsed ovarian cancer are described.
Publisher
National Academy of Sciences of the Republic of Armenia
Reference50 articles.
1. Aghajanian C., Blank S. V., Goff B. A. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol., 2012, v. 30, № 17, pp. 2039–2045.
2. Aghajanian C., Goff B., Nycum L. R. et al. Final overall survival and safety analysis of
3. OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients
4. with platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol., 2015, v. 139, № 1,pp. 10–16.
5. Della Pepa C., Tonini G., Pisano C., Di Napoli M., Cecere SC., Tambaro R., Facchini G., Pignata S. Ovarian cancer standard of care: are there real alternatives? Chin JCancer, 2015 Jan, 34(1):17-27. doi: 10.5732/cjc.014.10274. PMID: 25556615; PMCID:PMC4302086.